NCT07800351Not yet recruitingPhase 3
Nicorandil in Atherosclerosis Risk in Patients With Rheumatoid Arthritis
Effect of Nicorandil on Atherosclerosis Risk in Patients With Rheumatoid Arthritis: A Randomized Controlled Clinical Trial.
Source: ClinicalTrials.gov · Last updated 11 Sept 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn about the effects of adding nicorandil to conventional Disease-Modifying Antirheumatic Drugs(DMARDs) in treatment of patients with rheumatoid arthritis. The main questions it aims to answer are: Does adding nicorandil to conventional DMARDs in treatment of patients with rheumatoid arthritis reduce the risk of plaque buildup in arteries (atherosclerosis) ? and What medical problems may participants have when taking nicorandil ? Participants will: Take nicorandil added to DMARDs or DMARDs only for 3 months patient will be assessed at baseline and 3 months after for disease activity and risk of plaque formation over vascular wall Keep a diary of their symptoms and possible side effects
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- First submitted
- 29 Aug 2026
- Start date
- Sept 2026
- Primary completion date
- Feb 2027
- Lead sponsor
- Tanta University
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07800351
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 46
- From Sept 2026 to the primary completion date, Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- RA patients receiving biological DMARDs (bDMARDs).
- Patients on lipid-lowering drugs (e.g., statins, fibrates).
- Currently participating in or has participated in a study of an investigational agent or device within 30 days prior to screening.
Other illness
- Chronic autoimmune disease other than rheumatoid arthritis.
- Patients with metabolic or endocrine disease (e.g., diabetes mellitus, dyslipidemia).
- Severe renal or hepatic impairment.
- Any history of malignancy.
- Current acute or chronic infection.
- Known hypersensitivity or allergy to nicorandil or any of its components.
Other
- Current pregnancy or breastfeeding.
Who the study is looking for
- Adults aged 18-70 years, diagnosed with rheumatoid arthritis (RA) according to the 2010 ACR/EULAR classification criteria.
- Receiving conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy for at least 3 months.
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rheumatology, Rehabilitation and Physical Medicine department -Tanta university hospitals Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.